Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies
“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.
Comments 0
Log in to join the conversation.
No comments yet. Be the first to share your thoughts!